Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy

Condition(s) studied

Investigational drug(s) / intervention(s)

Breast conserving surgery: Remove only a small part of the breast

Radical modified mastectomy: Remove all the breast parenchyma, nipple and skin

Study summary

Inflammatory breast cancer is an aggressive and rare form of breast cancer, which accounts for 2-3% of all breast cancers. The classic presentation of inflammatory breast cancer includes erythema, edema, and peau d'orange of at least one/third of the breast.

Current treatment of inflammatory breast cancer include: neoadjuvant chemiotherapy, modified radical mastectomy and radiation therapy.

In the last two decades the development of new targeted therapies has significantly improved the efficacy of neoadjuvant chemiotherapy allowing a de-escalation of surgical treatment in patients with non-inflammatory breast cancer that achieve clinical complete response.

There are few retrospective studies that evaluate implications of surgical treatment on survival among these patients. This may justify trial aims to investigate the possible use of the breast conserving surgery in patients with inflammatory breast cancer that achieve clinical complete response after neoadjuvant chemiotherapy.

Eligibility

Primary outcome measure(s)

• local recurrence rate — 24 months
  Rate of recurrence in the breast parenchyma after conserving surgery vs radical mastectomy

Trial sites (1)

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy